DigestRedComo funciona
Red
/
Empresas
Ba
No verificado

Basilea Pharmaceutica AG, Allschwil

Sobre qué escribimos

Anuncios brevesBiotecnologíaFinanzasGestión empresarial/Administración de EmpresasPolítica Internacional

24 Comunicados de prensa

Ver todos los comunicados de prensa
12/01/2026
Biotecnología
Anuncios breves
Basilea joins INCATE to support antifungal innovation
Fuente
Basilea Pharmaceutica AG, Allschwil
Editor
GLOBENEWSWIRE
1.00
0
07/01/2026
Biotecnología
Basilea provides portfolio update and outlook
Fuente
Basilea Pharmaceutica AG, Allschwil
Editor
GLOBENEWSWIRE
1.00
0
06/01/2026
Biotecnología
Anuncios breves
Basilea and Prokaryotics enter collaboration to develop a novel broad-spectrum antifungal for the treatment of severe invasive infections
Fuente
Basilea Pharmaceutica AG, Allschwil
Editor
GLOBENEWSWIRE
1.00
0
10/12/2025
Biotecnología
Gestión empresarial/Administración de Empresas
Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic
Fuente
Basilea Pharmaceutica AG, Allschwil
Editor
GLOBENEWSWIRE
1.00
0
03/11/2025
Biotecnología
Anuncios breves
Política Internacional
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea
Fuente
Basilea Pharmaceutica AG, Allschwil
Editor
GLOBENEWSWIRE
1.00
0
24/09/2025
Biotecnología
Anuncios breves
Política Internacional
Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam
Fuente
Basilea Pharmaceutica AG, Allschwil
Editor
GLOBENEWSWIRE
1.00
0
15/09/2025
Biotecnología
Anuncios breves
Política Internacional
Basilea receives USD 25 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
Fuente
Basilea Pharmaceutica AG, Allschwil
Editor
GLOBENEWSWIRE
1.00
0
18/08/2025
Biotecnología
Anuncios breves
Política Internacional
Basilea on track with strong 2025 half-year results
Fuente
Basilea Pharmaceutica AG, Allschwil
Editor
GLOBENEWSWIRE
1.00
0
13/08/2025
Biotecnología
Anuncios breves
Política Internacional
Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic
Fuente
Basilea Pharmaceutica AG, Allschwil
Editor
GLOBENEWSWIRE
1.00
0
28/07/2025
Biotecnología
Anuncios breves
Basilea initiates phase 3 study with antifungal fosmanogepix in invasive mold infections
Fuente
Basilea Pharmaceutica AG, Allschwil
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0